Department of Neurology, Johns Hopkins University, Baltimore, MD.
Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA.
Mayo Clin Proc. 2019 Aug;94(8):1552-1555. doi: 10.1016/j.mayocp.2019.05.018.
Neurologists are worried about bleeding and complications from lumbar punctures in patients who use antiplatelet agents, such as aspirin and clopidogrel. We evaluated the bleeding risks of performing lumbar punctures in patients who are using or have recently used antiplatelet agents by retrospective review of lumbar punctures performed at the Johns Hopkins Hospital between 2004 and 2018 in patients who were actively using or recently used aspirin or clopidogrel, or both. Patients were stratified into time groups based on when the lumbar puncture was done relative to the time the antiplatelet drug was discontinued: <1 week, 1-4 weeks, >4 weeks. We recorded red blood cell counts for the earliest and latest spinal fluid collections to determine the risk of traumatic bleeding; we also noted any complications. Antiplatelet medication use within 1 week of lumbar puncture was associated with a 3% incidence of bloody tap and 4% incidence of traumatic tap that cleared. In the group of patients who waited for a lumbar puncture at least 4 weeks after discontinuation of antiplatelet drug, there was a 5% incidence of bloody or traumatic tap. There was no difference in rates of bleeding between aspirin versus aspirin plus clopidogrel. The rate of hematoma complications was highest in the group of patients on aspirin at the time of the procedure (0.7%). Aspirin or clopidogrel, or both, did not meaningfully increase hemorrhagic complications in patients undergoing lumbar punctures, regardless of when the antiplatelet drug was discontinued relative to the time of the procedure.
神经科医生担心在使用抗血小板药物(如阿司匹林和氯吡格雷)的患者中进行腰椎穿刺会出现出血和并发症。我们通过回顾 2004 年至 2018 年期间在约翰霍普金斯医院进行的腰椎穿刺,评估了在使用或近期使用抗血小板药物的患者中进行腰椎穿刺的出血风险,这些患者正在使用或近期使用阿司匹林或氯吡格雷,或两者兼有。患者根据腰椎穿刺相对于抗血小板药物停药时间的时间分组:<1 周、1-4 周、>4 周。我们记录了最早和最晚的脑脊液采集的红细胞计数,以确定创伤性出血的风险;我们还注意到任何并发症。抗血小板药物在腰椎穿刺前 1 周内使用与 3%的血性穿刺和 4%的创伤性穿刺发生率相关,这些穿刺均自行消退。在至少在停药后 4 周后进行腰椎穿刺的患者中,血性或创伤性穿刺的发生率为 5%。在接受腰椎穿刺时服用阿司匹林的患者中,血肿并发症的发生率最高(0.7%)。在进行腰椎穿刺的患者中,无论抗血小板药物何时停药相对于手术时间,阿司匹林或氯吡格雷,或两者兼有,均不会显著增加出血并发症的发生率。